浙江海正药业股份有限公司关于第四次以集中竞价交易方式回购公司股份的进展公告

Group 1 - The company has approved a plan to repurchase its shares through centralized bidding, with a total fund of no less than RMB 50 million and no more than RMB 100 million, at a price not exceeding RMB 13 per share, within a 12-month period [1] - As of May 22, 2025, the company has repurchased 582,000 shares, accounting for 0.05% of the total share capital, with a total expenditure of RMB 5,317,259, and the highest and lowest purchase prices being RMB 9.18 and RMB 9.08 per share respectively [2] - By the end of May 2025, the cumulative repurchased shares reached 1,347,000, representing 0.11% of the total share capital, with a total expenditure of RMB 12,249,660, and the highest and lowest purchase prices being RMB 9.22 and RMB 8.92 per share respectively [2] Group 2 - The company will strictly adhere to relevant regulations during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely information disclosure regarding the progress of the repurchase [4]